MedTrace Logo

Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

NCT00490074 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2026-04-08

No results posted yet for this study

Summary

The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers. Volunteers will be vaccinated by DNA-C and NYVAC-C vaccines, and the immune changes will be assessed, as well as safety of the vaccines. Volunteers will be followed during 72 weeks.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

DNA-C

1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM

BIOLOGICAL

NYVAC-C

NYVAC-C 1 ml IM

Sponsors & Collaborators

  • EuroVacc Foundation

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Yves LEVY, MD; PhD · Hôpital Henri Mondor-Créteil-France

  • Giuseppe PANTALEO, MD; PhD · Hospices CHUV-Lausanne-Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2009-10-31

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00490074 on ClinicalTrials.gov